Brian Eastwood, Global Head of Business Development, Almac Pharma Services, and Simon Hamilton, Head of Global Business Development, Almac Sciences explore the benefits of a single source provider for development through to commercialisation.
The Public Investment Fund (PIF) today announced the establishment of the Pharmaceutical Investment Company (Lifera), a commercial-scale contract development and manufacturing organisation.
Kai Lipinski, PhD, chief scientific officer of Vibalogics, a Recipharm company, focuses on oncolytic viruses (OVs); explaining how early-stage drug developers can overcome the challenges in scaling up and commercialising their products.
Ahead of CPHI Japan 2023, Ian Haydock, Citeline, predicts that the continued rise of biopharma innovation in China is the big macro trend in the APAC region that could potentially lead to shifts in outsourcing and manufacturing strategies regionally.
Christian Merup, CEO of Wellma, explains the winning recipe for successful co-manufacturers in Europe, including the underlying threads and unique capabilities of the leaders in the current CDMO market.
Christian Marcazzo, vice president/general manager of IDBS discusses how cloud-based solutions can create seamless communication between innovators and CDMOs.
Dr. Klaus Pollinger and Dr. Martina Breuer, Aenova Group, explore the challenges of development and commercial manufacturing of oral solid dosage forms, from a CDMO perspective.
Yuliyana Manolova, director Business Development Contract Manufacturing at Acino, explores the challenges generics manufacturing in Europe faces, and the actions pharma companies must take to better navigate the current market environment.
EPM spoke exclusively with Heiko Schmidt, Strategy & Consulting Life Sciences lead, Accenture AG, about why CDMOs should be prepared to track sustainability metrics now and how companies which wait, will likely be forced to catch-up at higher costs.
David O’Connell, director of Scientific Affairs at PCI Pharma Services, Tredegar site, shares insight on how CDMOs, like PCI, can provide end-to-end solutions in the growing demand of high potency manufacturing.
Almac Pharma Services’ VP Technical Operations, John McQuaid, discusses some growing requirements he sees from Almac’s client base as the industry addresses some of the trends associated with small molecule drug development.
